Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Veracyte Meets New Medicare Coverage Mandate For Molecular Dx

This article was originally published in The Gray Sheet

Executive Summary

Veracyte announced a positive coverage policy from Palmetto GBA Jan. 9 for its Afirma multi-gene expression classifier test, one of the first to go through the Medicare contractor’s new requirements.

You may also be interested in...



Veracyte Moves Into Lung Cancer MolDx With $21 Million Allegro Buy

The molecular diagnostic firm is expanding its focus beyond thyroid cancer to lung cancer, with plans to acquire Allegro Diagnostics and its gene expression assay. Allegro’s in-development system offers enhanced risk assessment for the approximately 40 percent of bronchoscopies that are inconclusive for lung cancer.

News In Brief

Edwards Lifesciences buys BMEYE for $42 mil. Sapien valve sales in Q3 fall below firm’s expectations. Hospira draws FDA warning letter. More news briefs.

Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics

The standards needed for reimbursement of molecular diagnostics are changing – especially with respect to genomics-based tests, with their potential impact on public health with respect to screening, prevention, and measuring response to treatment, as well as cost. As the complexity of the assay development and launch process has grown, so too has the emphasis on evidence and clinical effectiveness, as well as the importance of finding better ways to align test coding and reimbursement with clinical value. But a lack of coordination across agencies and commercial players makes an assessment of the impact of any changes on evidence demands problematic.

Related Content

Topics

UsernamePublicRestriction

Register

MT030893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel